Chemed Corp (CHE)

CHE (NYSE:Health Services)
neg -0.35
Today's Range: 102.32 - 103.50 | CHE Avg Daily Volume: 215,900
Last Update: 07/30/14 - 4:02 PM EDT
Volume: 217,119
YTD Performance: 34.16%
Open: $103.27
Previous Close: $102.79
52 Week Range: $64.16 - $103.15
Oustanding Shares: 17,539,101
Market Cap: 1,794,425,423
6-Month Chart
TheStreet Ratings Grade for CHE
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 1 1 1 1
Moderate Buy 0 0 0 0
Hold 2 2 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.33 2.33 2.00 2.00
Latest Dividend: 0.20
Latest Dividend Yield: 0.78%
Dividend Ex-Date: 05/27/14
Price Earnings Ratio: 24.59
Price Earnings Comparisons:
CHE Sector Avg. S&P 500
24.59 21.80 28.94
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
19.79% 42.72% 69.03%
Revenue -1.20 0.10 0.03
Net Income -13.50 -0.06 -0.02
EPS -10.00 0.17 0.05
Earnings for CHE:
Revenue 1.41B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $1.34 $1.51 $5.34 $5.79
Number of Analysts 1 1 1 1
High Estimate $1.34 $1.51 $5.34 $5.79
Low Estimate $1.34 $1.51 $5.34 $5.79
Prior Year $1.31 $1.40 $5.42 $5.34
Growth Rate (Year over Year) 2.29% 7.86% -1.48% 8.43%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Companies that provide end-of-life services have demographics on their side.
Feb 20, 2013 | 8:09 AM EST
Shares of CHE now seen reaching $91, Oppenheimer said. Fourth quarter beat. Outperform rating.
Oct 03, 2012 | 8:39 AM EDT
Shares of CHE now seen reaching $80, Oppenheimer said. Bullish following management meetings. Outperform rating.
These stocks stand to benefit if Americans can accept the fact that rising health care costs aren't magically going away.

Hospice Provider Is Ailing Real Money Pro($)

Recently accused of Medicare fraud, Chemed is facing costly legal problems.
Financial pain caused by a flat yield curve will cascade from the insurance industry into health care.
If only the entire economy felt as well.

Columnist Conversations

Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Before: Transparency is...
Market gets hit from impact of sanctions against Russia for second day in row but manages to rally a bit to en...
We took out some of the high end of support, but I'm still looking at this symmetrical pullback for entries on...
going into trading today roughly 37 million shares of X (US Steel) was held big X has traded 27 mi...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.